Abstract:Several drug targets have been amenable to drug discovery pursuit not until the characterization of the mitochondrial permeability transition pore (MPTP), a pore with an undefined molecular identity that forms on the inner mitochondrial membrane upon mitochondrial permeability transition (MPT) under the influence of calcium overload and oxidative stress. The opening of the pore which is presumed to cause cell death in certain human diseases also has implications under physiological parlance. Different models for this pore have been postulated following its first identification in the last six decades. The mitochondrial community has witnessed many protein candidates such as; voltage-dependent anion channel (VDAC), adenine nucleotide translocase (ANT), Mitochondrial phosphate carrier (PiC), Spastic Paralegin (SPG7), disordered proteins, and F1Fo ATPase. However, genetic studies have cast out most of these candidates with only F1Fo ATPase currently under intense argument. Cyclophilin D (CyPD) remains the widely accepted positive regulator of the MPTP known to date, but no drug candidate has emerged as its inhibitor, raising concern issues for therapeutics. Thus, in this review, we discuss various models of MPTP reported with the hope of stimulating further research in this field. We went beyond the classical description of the MPTP to ascribe a 'two-edged sword property' to the pore for therapeutic function in human disease because its inhibition and activation have pharmacological relevance. We suggested putative proteins upstream to CyPD that can regulate its activity and prevent cell deaths in neurodegenerative disease and ischemia-reperfusion injury.

Unlocking mitochondrial drug targets: The importance of mitochondrial transport proteins

Mitochondrial Targets for Pharmacological Intervention in Human Disease

Targeted mitochondrial delivery: A therapeutic new era for disease treatment

Mitochondrial-targeted liposome-based drug delivery – therapeutic potential and challenges

Mitochondria-Targeted Drugs

Advancements in Mitochondrial-Targeted Nanotherapeutics: Overcoming Biological Obstacles and Optimizing Drug Delivery

[Mitochondrial Drug Delivery for Cancer Therapy].

Targeting mitochondrial quality control: new therapeutic strategies for major diseases

Mitochondrial-Targeted Drug and DNA Delivery

Mitochondrial dysfunction: mechanisms and advances in therapy

Post-translational modifications in mitochondria: protein signaling in the powerhouse

Harnessing Mitochondrial Function in Human Diseases Using New Marine-Derived Strategies

Mitochondria as a therapeutic target for common pathologies

Targeting the mitochondrial permeability transition pore for drug discovery: Challenges and opportunities

Intercellular Mitochondrial Transfer: The Novel Therapeutic Mechanism for Diseases

Unlocking the mitochondria for nanomedicine-based Treatments: Overcoming biological Barriers, improving Designs, and selecting verification techniques

The Role of Mitochondria in Cellular Toxicity As a Potential Drug Target

Recent Progress in Mitochondria-Targeted Drug and Drug-Free Agents for Cancer Therapy

Mitochondrial Targeting of Probes and Therapeutics to the Powerhouse of the Cell

A sojourn on mitochondria targeted drug delivery systems for cancer: Strategies, clinical and future prospects

Investigating Therapies Targeting Druggable Targets of Mitochondria: Exploring the Efficacy for the Treatment of Cancer